ARTICLE | Emerging Company Profile
Boundless Bio: designing cancer therapies around extrachromosomal DNA
Boundless Bio launches with $46M series A to tackle unexplored extrachromosomal DNA target space in cancer
September 20, 2019 5:54 PM UTC
Updated on Nov 6, 2019 at 4:31 AM UTC
With a $46.4 million series A round led by Arch Venture Partners and City Hill Ventures, Boundless Bio is opening up a new target space in cancer by combining a commercially explored concept in tumor biology with President and CEO Zach Hornby’s expertise in precision medicine.
The San Diego-based company was founded around the idea that extrachromosomal DNA (ecDNA) is behind the amplification of certain oncogenes and the rapid evolution of cancer cells. ...